Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811551 | 1.00 | VCAM1 (0.74) | VCAM1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL16950942 | 0.87 | VCAM1 (0.71) | VCAM1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL22749329 | 0.86 | VCAM1 (0.56) | VCAM1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL340544 | 0.86 | MAPT (0.58) | VCAM1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL1258621 | 0.85 | VCAM1 (1.00) | VCAM1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL12555579 | 0.84 | VCAM1 (0.67) | VCAM1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL8625340 | 0.84 | VCAM1 (0.96) | VCAM1ALDH1A1MAPTHPGDLMNA | |
| SCHEMBL922714 | 0.84 | VCAM1 (0.77) | VCAM1ALDH1A1MAPTHPGDLMNA | |
| 4-Chloro-3-Nitrobenzoic Acid SCHEMBL6101 | 0.84 | VCAM1 (0.77) | VCAM1ALDH1A1MAPTHPGDLMNA | |
| 4-Chloro-3-Nitrobenzoic Acid SCHEMBL30234086 | 0.84 | VCAM1 (0.77) | VCAM1ALDH1A1MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444436-A | Synthesis method of aminophenylpyrazole compound | 曲靖师范学院 | 2023-07-18 | — | — | CN | claimed |
| CN-108863980-A | A method of synthesis 1- (5- benzothiazolyl) ethyl ketone | 浙江工业大学 | 2018-11-23 | — | — | CN | claimed |
| EP-4524129-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYL ACETONITRILE COMPOUND AND USE THEREOF | Maxunitech Inc. (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20250059132-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYLACETONITRILE COMPOUND AND APPLICATION THEREOF | MAXUNITECH INC (CN) | 2025-02-20 | — | — | US | disclosed |
| WO-2024131772-A1 | OXIME-CONTAINING COMPOUND HAVING STING INHIBITORY EFFECT, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 杭州中美华东制药有限公司 | 2024-06-27 | — | — | WO | disclosed |
| WO-2023245297-A1 | FERROPTOSIS INHIBITORS AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2023-12-28 | — | — | WO | disclosed |
| CN-117069614-A | Preparation method and application of 2-substituted aryl acetonitrile compound | 合力科技股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023216063-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYL ACETONITRILE COMPOUND AND USE THEREOF | 合力科技股份有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116444436-A | Synthesis method of aminophenylpyrazole compound | 曲靖师范学院 | 2023-07-18 | — | — | CN | disclosed |
| US-11370762-B2 | Vinylarene derivative and application | SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| EP-0288898-A1 | Substituted chinoxalyl-imidazolidine-2,4-diones, process for their preparation, their use as medicaments and pharmacological preparations | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-02 | — | — | EP | disclosed |
| EP-0260744-A2 | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-03-23 | — | — | EP | disclosed |
| US-4344957-A | Benz-acyl-benzimidazole derivatives and antiallergic compositions | CIBA-GEIGY CORPORATION (US) | 1982-08-17 | — | — | US | disclosed |
| US-4312990-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-26 | — | — | US | disclosed |
| US-4213993-A | ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1980-07-22 | — | — | US | disclosed |
| US-4141982-A | ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4036838-A | Process for the production of nitro derivatives of aromatic compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
| US-3948911-A | ANTIBACTERIAL, ANIMAL GROWTH REGULATORS | PFIZER INC. (US) | 1976-04-06 | — | — | US | disclosed |
| US-3933472-A | Substituted alkylaryl ketones and methods of use as herbicides | BUCKMAN LABORATORIES, INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | VCAM1 931/4885ALDH1A1 2858/4885MAPT 2833/4885 |
| US-20250059132-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYLACETONITRILE COMPOUND AND APPLICATION THEREOF | CYP1B1, CYP1A2, CYP2C9 | VCAM1 4813/4885ALDH1A1 209/4885MAPT 3935/4885 |
| US-11370762-B2 | Vinylarene derivative and application | IDO1, IDO2, INMT | VCAM1 118/4885ALDH1A1 233/4885MAPT 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.